Treatment with intravenous immunoglobulins in systemic lupus erythematosus: A series of 52 patients from a single centre

Clinical and Experimental Rheumatology

Volumn 32, Issue 1, 2014, Pages 41-47

  Camara, Ines ^a   Sciascia, Savino ^a,b   Simoes, Joana ^a   Pazzola, Giulia ^a   Salas, Veronica ^a   Karim, Yousuf ^c   Roccatello, Dario ^b   Cuadrado, Maria José ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Infections; Intravenous immunoglobulin; IVIG; Systemic lupus erythematosus

Indexed keywords

ADULT; COMMUNICABLE DISEASES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; LONDON; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894087253     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. KAZATCHKINE MD, KAVERI SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
2. SHOENFELD Y, KATZ U: IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005; 38: 123-37.
3. Gelfand EW: Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367: 2015-25.
4. ZANDMAN-GODDARD G, BLANK M, SHOENFELD Y: Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus 2009; 18: 884-8.
5. ZANDMAN-GODDARD G, KRAUTHAMMER A, SHOENFELD Y: The steroid-sparing effect of intravenous immunoglobulin in patients with autoimmune diseases. Expert Rev Clin Immunol 2007; 3: 773-80.
6. SVETLICKY N, BLANK M, ZANDMANGODDARD G: The beneficial effects of intravenous immunoglobulin for antineutrophil cytoplasmic antibody-positive vasculitis. Isr Med Assoc J 2012; 14: 568-9.
7. ZANDMAN-GODDARD G, KRAUTHAMMER A, LEVY Y, LANGEVITZ P, SHOENFELD Y: Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol 2012; 42: 247-55.
8. ZANDMAN-GODDARD G, LEVY Y, SHOENFELD Y: Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005; 29: 219-28.
9. LEVY Y, SHERER Y, GEORGE J, FABBRIZZI F, SHOENFELD Y: Use of intravenous immunoglobulin in idiopathic membranous nephropathy. Intern Med 1999; 38: 917.
10. LEVY Y, UZIEL Y, ZANDMAN G et al.: Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci 2005; 1051: 779-86.
11. TOMER Y, SHOENFELD Y: Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992; 10: 391-3.
12. KIVITY S, KATZ U, DANIEL N, NUSSINOVITCH U, PAPAGEORGIOU N, SHOENFELD Y: Evidence for the use of intravenous immunoglobulins-- a review of the literature. Clin Rev Allergy Immunol 2010; 38: 201-69.
13. ORBACH H, TISHLER M, SHOENFELD Y: Intravenous immunoglobulin and the kidney- -a two-edged sword. Semin Arthritis Rheum 2004; 34: 593-601.
14. BOLETIS JN, IOANNIDIS JP, BOKI KA, MOUTSOPOULOS HM: Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999; 354: 569-70.
15. LE POTTIER L, SAPIR T, BENDAOUD B, YOUINOU P, SHOENFELD Y, PERS JO: Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci 2007; 1110: 426-32.
16. KAVERI SV: Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 2012; 11: 792-4.
17. MADDUR MS, KAVERI SV, BAYRY J: Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev 2011; 10: 809-10.
18. COUSENS LP, TASSONE R, MAZER BD, RAMACHANDIRAN V, SCOTT DW, De GROOT AS: Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013; 12: 436-43.
19. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
20. WALLING HW, SONTHEIMER RD: Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009; 10: 365-81.
21. RUETTER A, LUGER TA: Efficacy and safety of intravenous immunoglobulin for immunemediated skin disease: current view. Am J Clin Dermatol 2004; 5: 153-60.
22. GOODFIELD M, DAVISON K, BOWDEN K: Intravenous immunoglobulin (IVIg) for therapy- resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 2004; 15: 46-50.
23. NAVARRA SV, GUZMAN RM, GALLACHER AE et al.: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
24. RUIZ-IRASTORZA G, KHAMASHTA MA, CASTELLINO G, HUGHES GR: Systemic lupus erythematosus. Lancet 2001; 357: 1027-32.
25. MICHELOUD D, CALDERON M, CAPARRROS M, D'CRUZ DP: Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann Rheum Dis 2007; 66: 986-7.
26. SURI V, VARMA S, JOSHI K, MALHOTRA P, KUMARI S, JAIN S: Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy. Rheumatology Int 2010; 30: 1503-5.
27. ZANDMAN-GODDARD G, SHOENFELD Y: Infections and SLE. Autoimmunity 2005; 38: 473-85.
28. SCIASCIA S, CEBERIO L, GARCIA-FERNANDEZ C, ROCCATELLO D, KARIM Y, CUADRADO MJ: Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev 2012; 12: 157-63.
29. GELFAND EW: Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006; 6: 592-9.
30. LACY JB, OHLSSON A: Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: meta-analyses. Arch Dis Child Fetal Neonatal Ed 1995;72: F151-5.
31. PILDAL J, GOTZSCHE PC: Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004; 39: 38-46.
32. MOSCA M, BOUMPAS DT, BRUCE IN et al.: Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol 2012; 30: S112-5.
33. CICCIA F, GIARDINA AR, ALESSI N et al.: Successful intravenous immunoglobulin treatment for steroid-resistant eosinophilic enteritis in a patient with systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29: 1018-20.
34. MOSCA M, TANI C, CARLI L, BOMBARDIERI S: Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29: S126-9.
35. ELKAYAM O, PARAN D, MILO R et al.: Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 2000; 59: 77-80.
36. LEARDINI G, RIGON C: The impact of the profile of biologics on treatment costs. Autoimmun Rev 2013; 12: 842-7.